Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver function may change how ammoxetine works

NCT ID NCT07694843

Recruiting now Knowledge-focused Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial investigates how ammoxetine, a drug given as an enteric-coated tablet, is processed by the body in people with mild or moderate liver impairment compared to those with normal liver function. Participants take a 20 mg dose daily for six days, and researchers measure drug levels in the blood and monitor safety. The goal is to understand if liver problems affect drug exposure, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ammoxetine hydrochloride
What this could lead to
If successful, this study could help doctors determine safe dosing of ammoxetine for patients with liver problems.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply to all patients. Liver impairment can unpredictably affect drug levels and safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS PARTICIPANTS WITH MILD HEPATIC IMPAIRMENT PARTICIPANTS WITH MODERATE HEPATIC IMPAIRMENT

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215006, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.